[1]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet 2020 Feb 15; 395(10223): 507-13.
[2]
Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Critical Care 2020 Dec; 24(1): 1-3.
[3]
Stilhano RS, Costa AJ, Nishino MS, et al. SARS-CoV-2 and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors. The FASEB Journal 2020 Nov; 34(11): 14103-19.
[4]
Al-Hakeim HK, Al-Jassas HK, Morris G, Maes M. Increased ACE2, sRAGE, and immune activation, but lowered calcium and magnesium in COVID-19. Recent Advances in Inflammation & Allergy Drug Discovery 2022 Mar; 18.
[5]
Turner AJ, Unger T, Steckelings UM, dos Santos RA. The protective arm of the renin angiotensin system (RAS). 2015; pp. 185-9.
[6]
Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease.International journal of peptides. 2012; p. 256294,2012.
[7]
Muñoz-Durango N, Fuentes CA, Castillo AE, et al. 2016. Role of the reninangiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension. International journal of molecular sciences. 17. (7): 797.
[8]
Zheng M-H, et al. The interplay between the renin-angiotensin-aldosterone system and parathyroid hormone. Frontiers in Endocrinology 2020 Aug 20; 11: 539.
[9]
Ruiz-Ortega M, Rupérez M, Esteban V, et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrology Dialysis Transplantation 2006 Jan 1; 21(1): 16-20.
[10]
Fyhrquist F, Metsärinne K, Tikkanen I. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. Journal of human hypertension 1995 Nov 1; 9: S19-24.
[11]
Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. European journal of clinical microbiology & infectious diseases 2021 May; 40(5): 905-19.
[12]
Perlot T, Penninger JM. ACE2–From the renin–angiotensin system to gut microbiota and malnutrition. Microbes and infection 2013 Nov 1; 15(13): 866-73.
[13]
Li W, Moore MJ, Vasilieva N, et al. Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003 Nov; 426(6965): 450-4.
[14]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. cell 2020 Apr 16; 181(2): 271-80.
[15]
Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. Journal of human hypertension 2007 Jan; 21(1): 20-7.
[16]
Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2. Frontiers in cellular and infection microbiology 2020; 317.
[17]
Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005 Jul; 436(7047): 112-6.
[18]
Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19). The Journal of pathology 2020 Jul; 251(3): 228-48.
[19]
Qin WH, Liu CL, Jiang YH, Hu B, Wang HY, Fu J. Gut ACE2 expression, tryptophan deficiency, and inflammatory responses the potential connection that should not be ignored during SARS-CoV-2 infection. Cellular and Molecular Gastroenterology and Hepatology 2021; 12(4): 1514-6.
[20]
Xu J, Chu M, Zhong F, et al. Digestive symptoms of COVID-19 and expression of ACE2 in digestive tract organs. Cell death discovery 2020 Aug 11; 6(1): 1-8.
[21]
Günther J, Fallarino F, Fuchs D, Wirthgen E. Editorial: immunomodulatory roles of tryptophan metabolites in inflammation and cancer. Front Immunol 11: 1497.
[22]
Cho SJ, Roman G, Yeboah F, Konishi Y. The road to advanced glycation end products: a mechanistic perspective. Current medicinal chemistry 2007 Jun 1; 14(15): 1653-71.
[23]
Gkogkolou P, Böhm M. Advanced glycation end products: Key players in skin aging? Dermato-endocrinology 2012 Jul 1; 4(3): 259-70.
[24]
Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovascular research 1998 Mar 1; 37(3): 586-600.
[25]
Vlassara H, Brownlee M, Cerami A. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proceedings of the National Academy of Sciences 1985 Sep; 82(17): 5588-92.
[26]
Basta G Lazzerini G, Massaro M, Simoncini T, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002 Feb 19; 105(7): 816-22.
[27]
Wang Y, Liu L. The membrane protein of severe acute respiratory syndrome coronavirus functions as a novel cytosolic pathogen-associated molecular pattern to promote beta interferon induction via a toll-like-receptor-related TRAF3-independent mechanism. MBio 2016 Feb 9; 7(1): e01872-15.
[28]
Oostra M, De Haan CA, De Groot RJ, Rottier PJ. Glycosylation of the severe acute respiratory syndrome coronavirus triple-spanning membrane proteins 3a and M. Journal of virology 2006 Mar 1; 80(5): 2326-36.
[29]
Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Current opinion in investigational drugs (London, England: 2000) 2006 Nov 1; 7(11): 985-91.
[30]
Reynolds PR, Schmitt RE, Kasteler SD, et al. Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. American journal of respiratory cell and molecular biology 2010 May; 42(5): 545-51.
Related Journals
Related Books
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Anti-Infective Drug Discovery
Coronaviruses
Moving From COVID-19 Mathematical Models to Vaccine Design: Theory, Practice and Experiences
COVID-19: Effects in Comorbidities and Special Populations
An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy
Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases
An Epidemiological Update on COVID -19
Frontiers in Clinical Drug Research – Anti Allergy Agents
Frontiers in Clinical Drug Research: Anti-Infectives
